MARKET

SPRB

SPRB

Spruce Biosciences, Inc.
NASDAQ
56.34
-0.16
-0.28%
Opening 15:25 05/11 EDT
OPEN
57.53
PREV CLOSE
56.50
HIGH
58.38
LOW
55.65
VOLUME
37.27K
TURNOVER
--
52 WEEK HIGH
240.00
52 WEEK LOW
4.350
MARKET CAP
142.09M
P/E (TTM)
-1.1084
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SPRB last week (0504-0508)?
Weekly Report · 9h ago
Spruce Biosciences appoints Brian Walls as VP, market access
TipRanks · 05/04 12:21
Spruce Biosciences names Brian Walls VP market access, Darren Johnson VP commercial operations
PUBT · 05/04 12:02
SPRUCE BIOSCIENCES FURTHER STRENGTHENS ITS COMMERCIAL LEADERSHIP TEAM WITH THE APPOINTMENTS OF BRIAN WALLS AS VICE PRESIDENT, MARKET ACCESS AND DARREN JOHNSON AS VICE PRESIDENT, COMMERCIAL OPERATIONS
Reuters · 05/04 12:00
Weekly Report: what happened at SPRB last week (0427-0501)?
Weekly Report · 05/04 09:31
Spruce Biosciences Price Target Announced at $140.00/Share by Craig-Hallum
Dow Jones · 04/27 18:00
Craig-Hallum Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $140
Benzinga · 04/27 17:50
Craig-Hallum bullish on Spruce Biosciences, initiates with a Buy
TipRanks · 04/27 14:10
More
About SPRB
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for neurological disorders with significant unmet medical need. It has a diverse portfolio of product candidates addressing diseases with high unmet medical need and clear biology for treatment, for which there are either no approved therapies treating the underlying disease or suboptimal treatment options. Its pipeline consists of TA-ERT, Tildacerfont and Cortibon, and SPR202. TA-ERT is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase. TA-ERT is intended as an enzyme replacement therapy for the treatment of patients with MPS IIIB who lack rhNAGLU enzyme activity. Tildacerfont has the potential to address hyperactive brain corticotropin-releasing factors neurotransmission and aberrant functioning of the hypothalamus-pituitary-adrenal axis in patients with MDD. SPR202 focuses on the treatment of Congenital Adrenal Hyperplasia and other indications.

Webull offers Spruce Biosciences, Inc stock information, including NASDAQ: SPRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SPRB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SPRB stock methods without spending real money on the virtual paper trading platform.